Core Viewpoint - Xianju Pharmaceutical (002332) announced the completion of the approval process for Vitamin D3 injection and related production technology transfer as of August 28, 2023 [1] Group 1 - The company has completed the bidding, auction, and listing work for the approval number of Vitamin D3 injection by December 2023 [1] - The company plans to actively promote the transfer of relevant licenses in the first half of 2024 and 2025 [1] - As of now, the company has completed the related work for the transfer of licenses [1]